Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 06, 2022

SELL
$74.28 - $92.69 $160,741 - $200,581
-2,164 Reduced 20.49%
8,398 $648,000
Q3 2021

Nov 12, 2021

BUY
$74.77 - $85.47 $74 - $85
1 Added 0.01%
10,562 $816,000
Q2 2021

Aug 09, 2021

SELL
$75.51 - $84.79 $924,317 - $1.04 Million
-12,241 Reduced 53.68%
10,561 $881,000
Q1 2021

May 10, 2021

BUY
$74.73 - $90.69 $1.7 Million - $2.07 Million
22,802 New
22,802 $1.72 Million
Q4 2020

Feb 10, 2021

SELL
$72.61 - $90.2 $1.66 Million - $2.06 Million
-22,811 Closed
0 $0
Q3 2020

Nov 06, 2020

SELL
$71.87 - $131.03 $480,738 - $876,459
-6,689 Reduced 22.67%
22,811 $1.74 Million
Q2 2020

Aug 10, 2020

SELL
$79.55 - $124.22 $772,669 - $1.21 Million
-9,713 Reduced 24.77%
29,500 $3.64 Million
Q1 2020

May 12, 2020

SELL
$71.37 - $96.85 $227,955 - $309,338
-3,194 Reduced 7.53%
39,213 $3.31 Million
Q4 2019

Feb 06, 2020

BUY
$64.27 - $86.37 $449 - $604
7 Added 0.02%
42,407 $3.59 Million
Q1 2019

May 10, 2019

SELL
$84.2 - $98.62 $101,208 - $118,541
-1,202 Reduced 2.76%
42,400 $3.77 Million
Q4 2018

Feb 08, 2019

SELL
$80.14 - $106.07 $408,714 - $540,957
-5,100 Reduced 10.47%
43,602 $3.71 Million
Q3 2018

Nov 13, 2018

BUY
$93.92 - $105.72 $2.58 Million - $2.9 Million
27,452 Added 129.19%
48,702 $4.72 Million
Q2 2018

Aug 09, 2018

BUY
$76.01 - $99.03 $1.47 Million - $1.91 Million
19,300 Added 989.74%
21,250 $2 Million
Q1 2018

May 15, 2018

BUY
$77.67 - $92.63 $151,456 - $180,628
1,950 New
1,950 $158,000
Q3 2017

Nov 14, 2017

SELL
$80.6 - $94.95 $845,896 - $996,500
-10,495 Closed
0 $0
Q2 2017

Aug 07, 2017

BUY
N/A
10,495
10,495 $953,000

Others Institutions Holding BMRN

About BIOMARIN PHARMACEUTICAL INC


  • Ticker BMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,824,000
  • Market Cap $13.1B
  • Description
  • BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
More about BMRN
Track This Portfolio

Track Gam Holding Ag Portfolio

Follow Gam Holding Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gam Holding Ag, based on Form 13F filings with the SEC.

News

Stay updated on Gam Holding Ag with notifications on news.